Trials / Completed
CompletedNCT01326689
A Comparative Study of KW-2246
Phase III Study of KW-2246 (A Double Blind Study of KW-2246 Compared to Placebo for Breakthrough Pain Episodes in Cancer Patients)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a placebo-controlled, double blind, comparative study to evaluate the efficacy and safety of KW-2246 as rescue medication at an optimal dose, which is determined by dose titration in treating breakthrough pain episodes in adult cancer patients receiving strong opioid analgesic on a fixed-schedule as well as rescue medication for breakthrough pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-2246 | Rescue medication at an optimal dose, which is determined by dose titration |
| DRUG | Placebo |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-03-31
- Last updated
- 2017-03-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01326689. Inclusion in this directory is not an endorsement.